Bristol-Myers Squibb Company (BMY) Stock Price, Quote & News

Company Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for oncology, hematology, immunology, cardiovascular, neuroscience, and other areas. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation and for the treatment of DVT/PE; Opdivo for various anti-cancer indications; Pomalyst/Imnovid for multiple myeloma; Orencia for...

Industry: Drug Manufacturers - General

Sector: Healthcare

Phone: 609 252 4621

Website: www.bms.com

Address:

Route 206 & Province Line Road, Princeton, United States

DoubleDownDave Feb. 3 at 8:43 PM

$BMY https://www.bitchute.com/video/Z7e1WLoOctZ2/ (5 minutes)

1 · Reply

ZacksResearch Feb. 3 at 7:43 PM

$BMY poised for growth with Reblozyl! 💊 Reblozyl sales surged 35% in the first nine months of 2025, hitting $1.66B, and expectations are high for Q4 with estimates around $636M-$641M. 🚀 But watch out for pressure from generic competition impacting legacy drugs like Revlimid and Pomalyst. Deep dive into BMY’s strategy here 👉 https://www.zacks.com/stock/news/2828105/will-reblozyl-shine-in-bristol-myers-fourth-quarter-results?cid=sm-stocktwits-2-2828105-body-31812&ADID=SYND_STOCKTWITS_TWEET_2_2828105_BODY_31812

0 · Reply

ZacksResearch Feb. 3 at 6:43 PM

Can Reblozyl carry $BMY into Q4 earnings? 👀 Bristol Myers is leaning on fast-growing Reblozyl, now a $2B+ franchise, to fuel results as generic pressure weighs on legacy drugs heading into fourth-quarter earnings. See what this means for BMY’s Q4 setup 👉 https://www.zacks.com/stock/news/2828105/will-reblozyl-shine-in-bristol-myers-fourth-quarter-results?cid=sm-stocktwits-2-2828105-teaser-31810&ADID=SYND_STOCKTWITS_TWEET_2_2828105_TEASER_31810

0 · Reply

Sunny3999 Feb. 3 at 4:16 PM

$PMN MCAP of $35 Million for an Alzheimer solution with Fast Track designation and DSMB approval without ARIA! This is a 1 billion MCAP in the making easily a 10 bagger $ABBV $BMY $MRK $SNY

0 · Reply

taxplanr Feb. 3 at 2:55 PM

CBD Oil with Ivermectin and Fenbendazole curing rectal cancer $BNTX $MRNA $BMY $MRK https://makisw.substack.com/p/ivermectin-fenbendazole-cbd-mcp-testimonial-123?utm_source=post-email-title&publication_id=1385328&post_id=186731115&utm_campaign=email-post-title&isFreemail=true&r=18m8lm&triedRedirect=true&utm_medium=email

0 · Reply

taxplanr Feb. 3 at 2:52 PM

Czech Republic using Ivermectin Fenbendazole and Mebendazole for NSCLC treatment $BNTX $BMY $MRNA $MRK https://makisw.substack.com/p/ivermectin-fenbendazole-and-mebendazole-6f3?utm_source=post-email-title&publication_id=1385328&post_id=186728862&utm_campaign=email-post-title&isFreemail=true&r=18m8lm&triedRedirect=true&utm_medium=email

1 · Reply

peloswing Feb. 3 at 2:21 PM

$BMY broke out on the weekly chart. Reporting earnings Thursday morning, with an implied move of +/-4.62% ↕️ - Bristol Myers Squibb just launched a campaign with Johnson & Johnson $JNJ

0 · Reply

Bandobaby49 Feb. 2 at 7:23 PM

$BMY 66$ by next Friday in two weeks

0 · Reply

MadMaverick Feb. 2 at 5:34 PM

🚨 $MTVA: The Next Frontier in the Obesity & GLP-1 Market 🔹 High-Growth Play: Direct exposure to the multi-billion dollar obesity and metabolic health sector. 🔹 Clinical Catalyst: Advancing DA-1726, a dual-agonist drug with best-in-class potential for weight loss. 🔹 Fully Funded: Recently secured $9.3M in capital to drive upcoming clinical milestones. 🔹 Pure Proxy: A high-upside public-market vehicle for the next wave of biotech breakthroughs. Why $MTVA stands out: 🔸 Targets both Obesity and MASH—two of the largest unmet needs in modern medicine. 🔸 Strong Phase 1b data showing significant weight loss results and a clean safety profile. 🔸 Positioned for momentum as the global demand for GLP-1 treatments skyrockets. MTVA looks rough so far in 2026 with price and sentiment tanking. However, despite the sell-off, volume is starting to surge, showing some life under the surface. Communicated Disclaimer - https://chartingdaily.com/metabolic-health $NVO $LLY $BMY $JNJ

1 · Reply

CatRocks Feb. 2 at 3:27 PM

$BNTX $MRNA $BMY $MRK Let us know when they start using bleach.

0 · Reply

Bristol Myers Squibb Introduces "Change the Target. Change What's Possible.

Jan 24, 2026, 11:52 AM EST - 10 days ago

Bristol Myers Squibb: The Rerating Was Fast - The Proof Will Be Slow (Rating Downgrade)

Jan 23, 2026, 3:52 PM EST - 11 days ago

Bristol-Myers Squibb: Solid Tumor Collaboration With Janux And Camzyos Expansion

Jan 22, 2026, 2:02 PM EST - 12 days ago

Janux Therapeutics Strikes Bristol Myers Biotech Deal Worth $800 Million

JANX

Jan 22, 2026, 7:38 AM EST - 12 days ago

Janux Therapeutics, Bristol Myers enter up to $850 million deal to develop cancer drug

JANX

Jan 22, 2026, 5:00 AM EST - 12 days ago

Top 10 Dividend Stocks For Uncertain Times

CDP DRH HST LNC MRK PINE PSX

Jan 21, 2026, 6:17 PM EST - 13 days ago

Final Trade: BMY, IGV, SOXX, GEN, AMZN

AMZN SOXX IGV

Jan 20, 2026, 11:00 AM EST - 14 days ago

2 Top Blue-Chip Stocks to Buy and Hold in 2026

MSFT

Jan 20, 2026, 8:08 AM EST - 14 days ago

Bristol Myers partners with Microsoft for AI-driven lung cancer detection

MSFT

Jan 20, 2026, 6:59 AM EST - 14 days ago

Bristol Myers Squibb Announces Collaboration with Microsoft to Advance AI-Driven Early Detection of Lung Cancer

Jan 15, 2026, 4:02 AM EST - 19 days ago

3 Stock Picks Where Technical Indicators Still Say Buy

BURL ITRN

Jan 12, 2026, 3:45 PM EST - 22 days ago

Bristol-Myers Squibb Company (BMY) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Jan 12, 2026, 6:59 AM EST - 22 days ago

Bristol Myers Squibb Announces Positive Topline Results from Phase 3 SCOUT-HCM Trial Evaluating Camzyos (mavacamten) in Adolescents with Symptomatic Obstructive Hypertrophic Cardiomyopathy (oHCM)

Jan 9, 2026, 12:57 PM EST - 25 days ago

Healthy Returns: What to expect from pharma at the JPM conference

AMGN AZN LLY MRK NVO PFE

Jan 2, 2026, 6:59 AM EST - 4 weeks ago

Bristol Myers Squibb to Present at J.P. Morgan's 44th Annual Healthcare Conference

Dec 31, 2025, 7:20 AM EST - 4 weeks ago

Wall Street's Most Accurate Analysts Spotlight On 3 Health Care Stocks Delivering High-Dividend Yields

CVS PRGO

Dec 27, 2025, 2:30 AM EST - 5 weeks ago

This Beaten-Down Pharma Stock Could Make a Turnaround in the New Year

Dec 26, 2025, 10:35 PM EST - 5 weeks ago

Chevron, Kimberly-Clark Among 16 Companies To Kick Off 2026 With Annual Dividend Increases In January

CVX KMB ABM ABT AMGN AVGO BCPC

Dec 24, 2025, 9:18 AM EST - 5 weeks ago

Bristol-Myers Squibb: Contrarian Buy For Dividend Hunters, Despite Mounting Growth Headwinds

Dec 24, 2025, 1:58 AM EST - 5 weeks ago

Bristol Myers Squibb: A Pharma Giant Trading Like Growth Is Over - It's Not

Dec 23, 2025, 1:56 PM EST - 6 weeks ago

Jenny Harrington's top dividend plays for 2026

AMCR ENB VICI

Dec 23, 2025, 11:30 AM EST - 6 weeks ago

Bristol-Myers Squibb: Pharma Giant Still Undervalued And Printing Cash Despite Patent Cliff

Dec 23, 2025, 11:17 AM EST - 6 weeks ago

Bristol-Myers Squibb Surges Into Year-End: Why BMY Still Looks Undervalued

Dec 23, 2025, 11:00 AM EST - 6 weeks ago

3 Top Value Stocks to Buy and Hold for 2026

CPB STZ

Dec 23, 2025, 8:45 AM EST - 6 weeks ago

Bristol-Myers Squibb: Still Undervalued And Generating 4.65% Dividend Yield

Dec 22, 2025, 6:18 PM EST - 6 weeks ago

Final Trade: NCNO, LION, SNAP, BMY

NCNO LION SNAP

Dec 19, 2025, 4:09 PM EST - 6 weeks ago

Nine pharmaceutical companies including Bristol-Myers Squibb, GSK and Merck agreed to lower the prices that certain federal government programs and patients pay

GSK MRK AMGN GILD NVS SNY

Dec 19, 2025, 3:14 PM EST - 6 weeks ago

Trump strikes deal with US drugmakers to cut Medicaid medicine costs

AMGN GILD GSK MRK NVS SNY

Dec 19, 2025, 3:05 PM EST - 6 weeks ago

Bristol Myers Squibb Announces Agreement with U.S. Government to Improve Affordability and Access to Critical Medicines for Americans

Dec 19, 2025, 2:34 PM EST - 6 weeks ago

Nine of the largest pharma companies ink deals with Trump to lower drug prices

AMGN GILD GSK MRK NVS SNY

Dec 19, 2025, 10:45 AM EST - 6 weeks ago

Trump to announce new drug-pricing deals later today

ABBV AMGN AZN GILD LLY MRK NVO

Dec 18, 2025, 6:59 AM EST - 6 weeks ago

Bristol Myers Squibb to Report Results for Fourth Quarter 2025 on February 5, 2026

Dec 17, 2025, 4:11 PM EST - 6 weeks ago

AbbVie, several other pharma companies near MFN deal with Trump, sources say

ABBV AMGN AZN LLY NVS PFE

Dec 16, 2025, 7:04 PM EST - 7 weeks ago

Harbour BioMed Enters into Global Strategic Collaboration and License Agreement with Bristol Myers Squibb to Discover and Develop Next-Generation Multi-Specific Antibodies

Dec 15, 2025, 6:22 PM EST - 7 weeks ago

Final Trade: JNJ, NVO, UBER, BMY

JNJ NVO UBER

Dec 15, 2025, 12:56 PM EST - 7 weeks ago

Bristol Myers Trades At Trough Valuation — Analyst Says Pipeline Upside Is Being Ignored

Dec 13, 2025, 8:00 AM EST - 7 weeks ago

Buy And Hold Portfolio For Next 10 Years: Potential $5,500 Monthly Income

AAPL ADX AMLP AMZN AVGO BST BUI

Dec 11, 2025, 6:32 PM EST - 7 weeks ago

Bristol-Myers Squibb Company (BMY) Shareholder/Analyst Call Transcript

Dec 11, 2025, 6:59 AM EST - 7 weeks ago

U.S. Food and Drug Administration (FDA) Grants Priority Review to Bristol Myers Squibb's Application for Opdivo® (nivolumab) Plus Chemotherapy Combination for Classical Hodgkin Lymphoma

Dec 10, 2025, 4:16 PM EST - 7 weeks ago

Bristol Myers Squibb Announces Dividend Increase

Dec 9, 2025, 7:00 AM EST - 2 months ago

BioNTech and Bristol Myers Squibb Present First Global Phase 2 Data for PD-L1xVEGF-A Bispecific Antibody Pumitamig Showing Encouraging Efficacy in Advanced Triple-Negative Breast Cancer

BNTX

Dec 8, 2025, 4:30 PM EST - 2 months ago

Bristol Myers Squibb Advances Lymphoma Research with New Targeted Protein Degradation and Cell Therapy Data at ASH 2025

$Bristol Myers Squibb's Breyanzi Approved by the U.S. FDA as the First and Only CAR T Cell Therapy for Adults with Relapsed or Refractory Marginal Zone Lymphoma (MZL)$

Dec 4, 2025, 8:15 PM EST - 2 months ago

Bristol Myers Squibb's Breyanzi Approved by the U.S. FDA as the First and Only CAR T Cell Therapy for Adults with Relapsed or Refractory Marginal Zone Lymphoma (MZL)

Dec 4, 2025, 5:38 PM EST - 2 months ago

Bristol-Myers Squibb Company (BMY) Presents at Citi Annual Global Healthcare Conference 2025 Transcript

Dec 3, 2025, 2:05 PM EST - 2 months ago

A delayed clinical trial actually boosted Bristol Myers Squibb's stock. Here's why.

Dec 3, 2025, 1:51 PM EST - 2 months ago

Bristol Myers Pushes Data Readout For Key Alzheimer's Psychosis Study After Irregularities

Dec 3, 2025, 11:00 AM EST - 2 months ago

Terray Therapeutics Achieves AI-Enabled Drug Discovery Milestone in Collaboration with Bristol Myers Squibb

Dec 3, 2025, 9:16 AM EST - 2 months ago

Bristol Myers Squibb Stock Climbs on Alzheimer's Trial Update. What to Know.

Dec 3, 2025, 6:59 AM EST - 2 months ago

Bristol Myers Squibb Announces Continuation of ADEPT-2 Phase 3 Study in Psychosis Associated with Alzheimer's Disease

Dec 2, 2025, 12:11 PM EST - 2 months ago

17 dividend-stock bargains from a value manager with a stellar track record

CIVI CMCSA CVS MOS MRK MTH OMC

DoubleDownDave Feb. 3 at 8:43 PM

$BMY https://www.bitchute.com/video/Z7e1WLoOctZ2/ (5 minutes)

1 · Reply

ZacksResearch Feb. 3 at 7:43 PM

0 · Reply

ZacksResearch Feb. 3 at 6:43 PM

0 · Reply

Sunny3999 Feb. 3 at 4:16 PM

$PMN MCAP of $35 Million for an Alzheimer solution with Fast Track designation and DSMB approval without ARIA! This is a 1 billion MCAP in the making easily a 10 bagger $ABBV $BMY $MRK $SNY

0 · Reply

taxplanr Feb. 3 at 2:55 PM

0 · Reply

taxplanr Feb. 3 at 2:52 PM

1 · Reply

peloswing Feb. 3 at 2:21 PM

$BMY broke out on the weekly chart. Reporting earnings Thursday morning, with an implied move of +/-4.62% ↕️ - Bristol Myers Squibb just launched a campaign with Johnson & Johnson $JNJ

0 · Reply

Bandobaby49 Feb. 2 at 7:23 PM

$BMY 66$ by next Friday in two weeks

0 · Reply

MadMaverick Feb. 2 at 5:34 PM

1 · Reply

CatRocks Feb. 2 at 3:27 PM

$BNTX $MRNA $BMY $MRK Let us know when they start using bleach.

0 · Reply

taxplanr Feb. 2 at 3:24 PM

Ivermectin and Mebendazole curing Breast Cancer in Israel $BNTX $MRNA $BMY $MRK https://makisw.substack.com/p/ivermectin-and-mebendazole-testimonial-34b?utm_source=post-email-title&publication_id=1385328&post_id=186531699&utm_campaign=email-post-title&isFreemail=true&r=18m8lm&triedRedirect=true&utm_medium=email

0 · Reply

taxplanr Feb. 2 at 3:15 PM

$BNTX $MRNA $BMY $MRK France https://makisw.substack.com/p/ivermectin-fenbendazole-and-mebendazole-f09?utm_source=post-email-title&publication_id=1385328&post_id=186462032&utm_campaign=email-post-title&isFreemail=true&r=18m8lm&triedRedirect=true&utm_medium=email

0 · Reply

taxplanr Feb. 2 at 3:13 PM

Ivermectin Fenbendazole and Mebendazole being used in France $BNTX $MRNA $BMY $MRK https://makisw.substack.com/p/ivermectin-fenbendazole-and-dmso?utm_source=post-email-title&publication_id=1385328&post_id=186452168&utm_campaign=email-post-title&isFreemail=true&r=18m8lm&triedRedirect=true&utm_medium=email

0 · Reply

taxplanr Feb. 2 at 2:58 PM

11 months to being Free from Pancreatic Cancer with Ivermecting Fenbendazole and Mebendazole $BNTX $MRNA $BMY $MRK https://makisw.substack.com/p/ivermectin-fenbendazole-mebendazole-cde?utm_source=post-email-title&publication_id=1385328&post_id=186399076&utm_campaign=email-post-title&isFreemail=true&r=18m8lm&triedRedirect=true&utm_medium=email

0 · Reply

ZacksResearch Feb. 2 at 2:47 PM

Big pharma earnings are up next — this could move the whole sector $LLY, $MRK, $NVO, $BMY and $PFE are set to report Q4 results as earnings season heats up, following a strong start for the pharma sector overall. Five heavyweight readouts in one stretch means expectations — and volatility — are building fast. What’s shaping up for these pharma giants this earnings season? Full breakdown here 👉 https://www.zacks.com/stock/news/2827159/whats-in-store-for-these-5-pharma-bigwigs-this-earnings-season?cid=sm-stocktwits-2-2827159-teaser-31428&ADID=SYND_STOCKTWITS_TWEET_2_2827159_TEASER_31428

0 · Reply

ZacksResearch Feb. 2 at 2:22 PM

Is $BMY facing challenges despite an 8.1% drop over the past year? 📉🤔 - Solid growth in new drugs like Reblozyl and Breyanzi - Strong demand for Eliquis, but legacy drug sales weigh on revenue - New collaborations and acquisitions bolstering the pipeline See if BMY's earnings can provide stability 👉 https://www.zacks.com/stock/news/2826806/should-you-buy-hold-or-sell-bmy-stock-ahead-of-q4-earnings?cid=sm-stocktwits-2-2826806-body-31382&ADID=SYND_STOCKTWITS_TWEET_2_2826806_BODY_31382

0 · Reply

ZacksResearch Feb. 2 at 1:22 PM

Buy, Hold, or Sell $BMY before Q4 2025 earnings? ⚠️💊 BMY heads into Q4 2025 earnings with strong Opdivo momentum, even as generic pressure continues to weigh on legacy drug sales — a clear push-pull setup investors can’t ignore. See the full bull vs. bear breakdown here 👉 https://www.zacks.com/stock/news/2826806/should-you-buy-hold-or-sell-bmy-stock-ahead-of-q4-earnings?cid=sm-stocktwits-2-2826806-teaser-31381&ADID=SYND_STOCKTWITS_TWEET_2_2826806_TEASER_31381

0 · Reply

taxplanr Feb. 2 at 1:16 AM

AZ taking it to the pig pHarma science fraud factory $BNTX $MRNA $MRK $BMY $PFE https://www.science.org/content/article/scientific-fraud-has-become-industry-alarming-analysis-finds

1 · Reply

taxplanr Feb. 1 at 10:46 PM

Keeps happening $BNTX $MRNA $BMY $MRK https://www.tiktok.com/t/ZThf1m84Q/

0 · Reply

3DBuilds Jan. 31 at 5:13 AM

$BEAM $BMY $JNJ $NTLA $REGN

0 · Reply

ZacksResearch Jan. 30 at 7:28 PM

$BMY's new collab with Janux: A potential $800M milestone opportunity? 💰 Bristol Myers Squibb is teaming with Janux Therapeutics on a novel tumor-activated therapeutic, with Janux eligible for up to $800M in development, regulatory, and commercial milestones, plus royalties. This could be a game-changer for BMY's pipeline amid generic pressures. Discover full details here 👉 https://www.zacks.com/stock/news/2825961/will-bmys-oncology-collaborations-drive-its-next-growth-phase?cid=sm-stocktwits-2-2825961-body-31320&ADID=SYND_STOCKTWITS_TWEET_2_2825961_BODY_31320

0 · Reply

ZacksResearch Jan. 30 at 6:28 PM

$BMY leaning into oncology — could this be the next growth lever? 👀 The company is boosting its oncology pipeline with a Janux deal focused on tumor-activated therapy, alongside encouraging pumitamig data and multiple cancer collaborations. See how these moves could shape BMY’s next phase 👉 https://www.zacks.com/stock/news/2825961/will-bmys-oncology-collaborations-drive-its-next-growth-phase?cid=sm-stocktwits-2-2825961-teaser-31319&ADID=SYND_STOCKTWITS_TWEET_2_2825961_TEASER_31319

0 · Reply

Market Cap	112.07B
Revenue (ttm)	48.30B
Net Income (ttm)	-8.95B
EPS (ttm)	N/A
PE Ratio	8.27
Forward PE	8.93
Profit Margin	-18.53%
Debt to Equity Ratio	2.63

Volume	11,081,200
Avg Vol	14,403,702
Day's Range	N/A - N/A
Shares Out	2.04B
Stochastic %K	77%
Beta	0.29
Analysts	Sell
Price Target	$57.25